A41.9
Conditions
Interventions
Group 1: Adult, critically ill patients with sepsis (as defined by sepsis 3) treated in the ICU during the enrollment period 01/2024 - 11/2025 and receiving
piperacillin/tazobactam or meropenem as an
Sponsors
Universtitätsklinikum Knappschaftskrankenhaus Bochum
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: - Intensive care treatment - Inclusion within 72 h after diagnosis of sepsis (according to sepsis-3-definition) - Inclusion within 24 h after initiation of treatment with piperacillin/tazobactam or meropenem - Antibiotic treatment with meropenem or piperacillin/tazobactam.
Exclusion criteria
Exclusion criteria: - Refusal of study participation by patient/authorized representative - Pregnancyandbreastfeeding - Manifest anemia with hemoglobin value <8g/dl
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Predict antibiotic serum concentration (ASC) of piperacillin/tazobactam or meropenem on day 1 therapy. | — |
Secondary
| Measure | Time frame |
|---|---|
| - Prediction of ASK of piperacillin/tazobactam or meropenem during the course of therapy on days 2,3,4,5,6,7 and 8. - Influence of ASC on 30-day mortality. - Influence of ASC on the course of the SOFA score (Delta-SOFA) - Occurrence of antibiotic resistance under therapy - Influence of ASC on the incidence of acute renal renal failure - Influence of ASC on the incidence of acute liver injury | — |
Countries
Germany
Contacts
Public ContactTim Rahmel
Universitätsklinikum Knappschaftskrankenhaus Bochum
Outcome results
None listed